Legal Business

Simpson Thacher, Davis Polk and Bär & Karrer win mandates on $43bn ChemChina-Syngenta deal

legal-business-default

Simpson Thacher & Bartlett, Davis Polk & Wardwell, and Swiss firm Bär & Karrer have landed key advisory roles on China National Chemical Corp’s (ChemChina’s) $43bn bid for Swiss seeds and pesticides group Syngenta, in what will be the largest ever acquisition by a Chinese firm.

Simpson Thacher is advising China’s state-owned ChemChina on M&A, acquisition finance and regulatory aspects with a team led by partners Alan Klein, Shaolin Luo, Chris May and Sinead O’Shea, alongside Homburger.

Davis Polk & Wardwell and local Swiss firm Bär & Karrer are acting for Syngenta.

HSBC is arranging the debt financing for the deal, with advice from Linklaters, who is acting with a team led by London banking partner Brian Gray. Clifford Chance is advising ChemChina’s financial adviser China CITIC Bank with a team led by Maggie Lo.

Clifford Chance has acted for ChemChina in the past, advising on its $7.7bn bid to buy Italian tire-maker Pirelli. The deal announced last year, gave Chinese investors a significant foothold in Italy’s manufacturing industry while signalling continued Chinese investment into Europe. Davis Polk and Bär & Karrer previously worked together advising Syngenta in its defence of a takeover proposal by agriculture company Monsanto.

Syngenta said today (3 February) that the agreed offer amounted to $465 a share, plus a special dividend of 5 Swiss francs ($4.91) a share to be paid immediately before the deal’s closing. The company also announced that a ‘future initial public offering is intended’ while the transaction will ‘enable further expansion of Syngenta’s presence in emerging markets and notably in China.’

sarah.downey@legalease.co.uk

Legal Business

US and Irish firms act on $16.5bn Tyco-Johnson Controls merger

legal-business-default

Simpson Thacher & Bartlett, Wachtell, Lipton, Rosen & Katz, A&L Goodbody and Arthur Cox have all landed roles advising on the $16.5bn merger of industrial company Johnson Controls and security provider Tyco – a deal that will lower the new company’s tax bill.

The US maker of car batteries and heating equipment Johnson Controls will combine with Cork-based Tyco, with the merged companies’ headquarters to be based in Tyco’s homeland Ireland.

The combined company will be renamed Johnson Controls and will be domiciled in low-tax Ireland. The deal is expected to save the new company at least $150m in annual tax. The combination will be tax-free to Tyco shareholders and taxable to Johnson Controls shareholders.

Simpson Thacher represented Tyco International led by New York-based M&A partners Alan Klein and Elizabeth Cooper. Irish firm Arthur Cox also provided advice with corporate partner Stephen Ranalow leading alongside with corporate partners Maura McLaughlin and Geoff Moore, with Fintan Clancy on tax and Phil Cody on finance.

Skadden Arps represented Tyco’s lead financial adviser Lazard with corporate partners Eileen Nugent and Michael Chitwood acting. Citi provided the committed financing for the transaction and Goldman Sachs served as financial adviser for Tyco.

Wachtell and A&L Goodbody advised Johnson Controls, with Cleary Gottlieb Steen & Hamilton leading on competition aspects. Cleary’s antitrust team on the deal is led by Washington based partner Brian Byrne, and Brussels based partner Nicholas Levy. Centerview Partners served as lead financial adviser, with Barclays also advising.

Under the terms of the agreement, Johnson Controls shareholders will own approximately 56% of the equity of the combined company and receive aggregate cash consideration of approximately $3.9bn. Current Tyco shareholders will own approximately 44% of the equity of the combined company.

The transaction is expected to complete by the end of fiscal year 2016 subject conditions including regulatory approvals and consent from the shareholders of both companies.

By moving its headquarters to Cork, Johnson Controls becomes the latest US firm to exploit Ireland’s lower tax regime, in an inversion deal similar to last year’s planned Pfizer-Allergan deal. Firms to win mandates on that deal include Wachtell, Skadden, Arps, Slate, Meagher & Flom; and A&L Goodbody acting as Pfizer’s legal advisers, alongside Morgan Lewis and Clifford Chance. Debevoise & Plimpton acts for Pfizer’s financial advisers.

Allergan turned to Cleary Gottlieb Steen & Hamilton, Latham & Watkins and Arthur Cox for the deal.

jaishree.kalia@legalease.co.uk

Legal Business

Partner promotions: Simpson Thacher makes up three London partners while Sullivan focuses on US

legal-business-default

Simpson Thacher & Bartlett has promoted nine new partners across the firm, including three in London, while fellow Wall Street elite firm Sullivan & Cromwell has only promoted in the US in its latest round.

Carol Daniel, who is one of the new Simpson Thacher partners promoted in the London office, has experience working for private equity sponsors, issuers and underwriters on their high yield bond offerings, restructurings, initial public offerings and other corporate finance transactions, as well as representing corporations and private equity sponsors in a variety of leveraged buyouts transactions and general corporate and securities law matters.

The firm also made up Wheatly MacNamara, who is a member of the firm’s real estate department and focuses on private equity real estate acquisitions.

Private funds practitioner Seema Shah is the third lawyer in the City who was made up to partner. Shah’s focus is in the sponsoring and operation of private investments funds.

Simpson also made up six partners in New York across a variety of practice areas including capital markets, litigation, banking, derivatives and M&A.

Sullivan & Cromwell has also carried out a round of internal promotions, although all of these have been made in the US. The firm made up six partners: five in New York and one in Washington DC. The majority of the New York-based lawyers work across the firm’s corporate practice. .

In Washington DC Kathleen McArthur’s practice focuses on complex commercial litigation, regulatory enforcement proceedings and internal investigations. McArthur has represented companies in a variety of inquiries by the Commodity Futures Trading Commission, the Securities and Exchange Commission and the US Department of Justice, as well as in securities class actions, shareholder derivative litigation and other commercial disputes.

All partnership promotions are effective 1 January 2016.

The full list of partner promotions is as follows:

Simpson Thacher

David Azarkh, capital markets, New York

Carol Daniel, capital markets, London

Susannah Geltman, litigation, New York

Brian Gluck, banking, New York

Jonathan Lindabury, derivatives, New York

Wheatly MacNamara, real estate, London

Seema Shah, funds, London

Sebastian Tiller, M&A, New York

Jessica Tuchinsky, banking, New York

Sullivan & Cromwell

Ari Blaut, corporate, New York

Heather Coleman, corporate, New York

Scott Crofton, corporate, New York

Joseph Hearn, corporate, New York

Kathleen McArthur, litigation, Washington DC

Matthew Porpora, litigation, New York

kathryn.mccann@legalease.co.uk

Subscribers can read more about US firms at: ‘The conservation game – up close with New York’s original inner circle’

 

Legal Business

Dealwatch: Davis Polk and Simpson Thacher lead as AstraZeneca takes over ZS Pharma for $2.7bn

legal-business-default

Wall Street leaders Davis Polk & Wardell and Simpson Thacher & Bartlett are lead advisers on Anglo-Swedish pharma giant AstraZeneca’s $2.7bn acquisition of California-based biopharmaceutical company ZS Pharma.

The deal is the latest in a wave of takeover deals in the healthcare industry, including the potential $100bn merger of AstraZeneca and Pfizer, which came to a halt last year. Last week Dublin-based Shire moved to acquire US firm Dyax for $5.9bn, in a deal which Ropes & Gray‎, Slaughter and May, Davis Polk and Sullivan & Cromwell all advised on.

Under this latest agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction.

Davis Polk’s team out of New York represented AstraZeneca, comprising corporate partners Marc Williams and Brian Wolfe, partner Edmond FitzGerald for compensation advice, tax partner Neil Barr and Joel Cohen on antitrust and competition issues

ZS Pharma instructed Simpson Thacher with corporate partners Kevin Kennedy and Kirsten Jensen, employment partner Tristan Brown, tax partner Katharine Moir and IP partner Noah Leibowitz.

The transaction is expected to close by the end of 2015.

AstraZeneca has used a range of firms in the past, including RPC on its move to a new headquarters in Cambridge in 2013, and Covington & Burling when it purchased Spanish healthcare group Almirall for $2.1bn in 2014.

jaishree.kalia@legalease.co.uk

 

 

 

Legal Business

White & Case’s City office wins first work from CVC as PE house leads on $2bn Alvogen acquisition

legal-business-default

White & Case, Simpson Thacher & Bartlett and Slaughter and May have all won roles as CVC Capital Partners, Vatera Healthcare and Singaporean sovereign wealth fund Temasek teamed up to buy a controlling stake in pharmaceutical firm Alvogen.

Although White & Case has an historic relationship with CVC stateside, this is the first work led out of London for the European private equity fund that led on the deal for the consortium. The firm’s team was led by partners Ian Bagshaw (pictured) in London and Oliver Brahmst from New York and included New York partner Brian Smarsh, plus Justin Wagstaff and Marcus Booth, both in London.

Bagshaw told Legal Business the deal played to the firm’s strengths: ‘It was one of those deals where you needed to be strong in New York and strong in London to get the deal away as the M&A was done in the US while I could lead the deal and the investment work out of London.’

The deal, which reportedly values Alvogen at $2bn, saw a club of investors including CVC, Temasek and Vatera Healthcare purchase a controlling stake in the pharma company from Pamplona Capital Management. Simpson Thacher led for Alvogen and Pamplona with a team including Peter Martelli in New York and Clare Gaskell in London. Lowenstein Sandler provided additional advice to Pamplona, which only bought its stake in the company with operations in 35 countries last year.

Bagshaw added: ‘Ultimately, it was a complex deal because of the nature of the consortia and the different drivers within it meant there were a number of points of view to reconcile. The deal played to the strengths of the firm, as Alvogen’s revenues are US but the growth areas are Central Europe and Asia. We were able to look at the due diligence in the US, and then when it comes to looking at comparable issues in Romania or Korea or Taiwan, we had teams on the ground to apply local knowledge.’

Those other point of views saw Slaughters win a role acting for Temasek with a team led by Nigel Boardman while biotech/pharmaceutical investment specialist Vatera was advised by Wilkie Farr & Gallagher.

The company has over 200 projects in development and registrations plus 350 marketed products. Aztiq Pharma, an investment vehicle led by Alvogen’s chief executive Robert Wessman, is retaining a stake while Pamplona will also keep a small stake.

CVC has previously turned to a raft of firms for its corporate work including Clifford Chance and Cleary Gottlieb Steen & Hamilton.

michael.west@legalease.co.uk

Legal Business

Simpson Thacher’s Glover: Tied up and tied down – a peculiar way to police the private funds market

legal-business-default

The financial crisis ushered a wave of new regulations aimed at mitigating systemic risk to the financial system. While no-one has been able to rationally point a finger at private funds as a cause of the crisis, the industry has nonetheless seen a dramatic rise in the level of regulation and scrutiny. As legal and compliance costs soar, one is hard-pressed to find a private fund manager or – perhaps more importantly – an investor welcoming these changes.

In Europe, the Alternative Investment Fund Managers Directive (AIFMD) came into force in July 2013 and imposed a wide range of requirements on private fund managers in areas ranging from marketing, conduct of business, custody and safe-keeping of assets, capital requirements and reporting, and disclosures to investors and regulators. These regulatory requirements have largely been imposed using a one-size-fits-all approach, under which a single set of rules applies to funds with significantly different operating models (eg buyouts, venture capital, real estate, credit/debt funds, hedge funds). This, together with the vagueness of the legislation and the differing interpretations of its provisions among EU member states, has resulted in a complex and unwieldy regime, which has created significant legal uncertainty for private fund managers looking to market their fund into the EU or seeking to manage an EU fund.

On the other side of the Atlantic, the major legislative response to the financial crisis has been the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank). Dodd-Frank eliminated the ‘private adviser’ exemption that many investment advisers to private funds relied on and replaced it with several narrower exemptions so that Securities and Exchange Commission (SEC) registration requirements now extend to virtually all US-based private fund managers and many foreign fund managers with US operations. SEC registration requires compliance with a number of onerous obligations, including the requirement to have a chief compliance officer, and the requirement to comply with extensive reporting (eg Form ADV and Form PF filings) and record-keeping obligations.

Both AIFMD and Dodd-Frank have come under heavy fire from participants in the private funds industry. While resistance to change is to be expected, there are legitimate concerns that the regulatory burden imposed on private funds is not matched by a public policy benefit. It is likely too soon to tell if the new regulatory regimes provide an effective framework to oversee and mitigate systemic risk; what is clear, however, is that the new regulations are having a transformative (and not necessarily welcome) effect on the private funds market with likely lasting consequences.

IMPACT ON PRIVATE FUND MANAGERS

The cumulative weight of new regulation has inevitably meant the cost of doing business has increased significantly. The increase in costs is principally a function of an increase in back-office compliance staff and in services provided by outside legal counsel, consultants and third-party services providers (eg depositories), as well as investment in additional technology to enable private fund managers to improve their data management and reporting processes.

The increase in regulation has also resulted in firms having to institutionalise their operations to cope with more bureaucracy and red tape. This has resulted in a more systematic approach to operations and a greater emphasis on process, checklists and prompts to ensure that all boxes are checked correctly and on time.

IMPACT ON THE PRIVATE FUNDS INDUSTRY

While many larger firms already have much of the infrastructure in place to absorb incremental compliance work, smaller and mid-size firms are having to employ new dedicated resources to manage the increased burden. As a consequence, the increased compliance burden is likely to have a disproportionately adverse effect on smaller/mid-size firms, who are likely to see a greater impact on profitability. In turn, such incremental costs may serve as a force to drive a consolidation of assets under management in an effort to exploit administrative economies of scale, resulting in less choice for investors. Further, as the private funds industry becomes a more capital-intensive business with greater upfront working capital requirements, barriers to entry will increase. As such, we are likely to witness fewer first-time fundraisings and team spin-outs in future, again to the detriment of investors. In addition, the prospect of complying with AIFMD has also deterred a number of non-EU fund managers from actively marketing their funds in Europe, again resulting in less choice for European investors.

Whether the new regulations will play a role in preventing or in formulating an effective response to the next financial crisis remains to be seen. In the meantime, as the frictional costs of doing business increase and are ultimately passed onto investors, the impact on returns for traditional investors in private funds will be negative. Private fund managers will continue to seek solutions to streamline their compliance operations to meet regulatory obligations more efficiently. It seems clear, however, that the larger fund managers have an opportunity to entrench their dominant positions and increase their competitive advantages over smaller rivals. Conversely, the future outlook for managers of small and mid-size private funds looks distinctly more challenging.

Jason Glover is a partner in Simpson Thacher & Bartlett’s London office.

Legal Business

Significant mandates: Hogan Lovells among raft of firms on GE’s financial restructuring

legal-business-default

Hogan Lovells plus a host of US firms have won roles on GE’s major financial restructuring, including the $26.5bn sale of its real estate assets, as it tries to create a ‘simpler and more valuable company’ by selling most of GE Capital’s assets.

Under the agreement, GE will sell the bulk of the GE Capital Real Estate assets – in what has been dubbed one of the largest real estate deals on record – to funds managed by Blackstone with Wells Fargo also acquiring a portion of the performing loans at closing. The company also has letters of intent with other buyers for an additional $4bn of commercial real estate assets, totalling a $26.5bn disposal.

Hogan Lovells’ cross-border team, which comprised over 75 lawyers, advised GE on the real estate sale led by partners Warren Gorrell, Bruce Gil‎christ, Prentiss Feagles, Lauren Bellerjeau, Waajid Siddiqui and Lee Berner, based in New York and Washington DC. The GE legal team was led by former Hogan Lovells partner Mark Landis, currently executive legal counsel–M&A at the company.

On the other side was Dechert representing Wells Fargo with US based partner Richard Jones leading, alongside London-based Jeremy Trinder, Jason Butwick, Mark Stapleton plus US partners Kahlil Yearwood, Philippe Phaneuf, David Linder, Daniel Dunn and, out of France, Philippe Thomas.

Simpson Thacher & Bartlett represented Blackstone with partners Greg Ressa, Sas Mehrara and Krista Miniutti leading. Bank of America and Kimberlite Advisors provided financial advice on the real estate deal.

On the wider restructuring of the business GE took advice from Weil, Gotshal & Manges on corporate and restructuring matters with Sullivan & Cromwell advising on the regulatory aspects led by Sullivan’s senior chairman Rodgin Cohen. 

Davis Polk & Wardwell led on tax matters for the company with a team including corporate partners Richard Sandler and John Meade, tax partners Neil Barr, Michael Farber and Michael Mollerus, partners Randall Guynn and Luigi de Ghenghi handling regulatory matters and investment management partners Nora Jordan and Gregory Rowland. 

GE expects to return more than $90bn to investors through to 2018, the majority of which will come from the $50bn share repurchase program with the remainder generated from the current dividend and the spinoff of its remaining 85% stake in Synchrony. The company expects that by 2018 over 90% of its earnings will be generated by its high-return industrial businesses, up from 58% last year.

jaishree.kalia@legalease.co.uk

Legal Business

Dealwatch: Simpson Thacher leads for KKR as thetrainline.com opts for sale over IPO

legal-business-default

Private equity powerhouse KKR has purchased travel ticket seller thetrainline.com, with its go-to law firm Simpson Thacher & Bartlett advising on a deal that diverted the company from carrying out its announced IPO on the London Stock Exchange.

Simpson Thacher has strong ties to the private equity house in the US, with London managing partner Gregory Conway the relationship manager for KKR in the City.

Thetrainline.com’s owner, UK private equity house Exponent, announced plans to list Britain’s largest online rail booking company for £500m earlier this year. However, KKR’s interest saw that plan derailed in favour of a quicker departure, with Exponent more than tripling its investment after purchasing Trainline in 2006 for £160m.

Since launching in 1999 Trainline has gone on to become the most downloaded travel app in the UK. The company has 4.7m active customers and received nearly 21m visits each month.

Travers Smith’s head of corporate Spencer Summerfield, alongside corporate partner Adrian West and US securities partner Charles Casassa, were originally instructed by Trainline to execute the IPO and were retained to handle the sale to KKR.

Herbert Smith Freehills corporate partner Chris Haynes and the firm’s global head of capital markets Steve Thierbach were enlisted by Morgan Stanley and JP Morgan, the banks charged with spearheading an IPO.

tom.moore@legalease.co.uk

Legal Business

Life During Law: Jason Glover, Simpson Thacher & Bartlett

legal-business-default

Clifford Chance (CC) was a great place to be in the 1990s. Geoffrey Howe deserves a huge amount of credit. He instilled that we were on a journey everyone else was seeking to replicate. The car was travelling fast. The concept of delivering that globalisation was a very powerful thing.

I didn’t have a plan but a lot of fortune. I took a view early on that there were hundreds of great technical lawyers and I would never be able to distinguish on just that.

Legal Business

US associate bonuses: Simpson first to unveil, Cravath follows and Skadden tops with $110,000 bonus

legal-business-default

The US bonus season, usually led by Cravath Swaine & Moore, has this year seen Simpson Thacher & Bartlett kick-start the process ahead of the traditional schedule, and set a very high bar for the rest of the American elite firms.

Simpson awarded $15,000 in bonus to its junior associates increasing to $100,000 for the more senior ranks, with the firm’s midlevel and senior associates seeing the biggest increases from last year. Traditional market leader to unveil bonuses Cravath, Swaine & Moore followed suit and matched Simpson Thacher’ bonus scales for each associate level.

However, breaking the mould so far are Skadden Arps Slate Meagher & Flom and Davis Polk Wardwell who have awarded their associates more generously. While Skadden Arps pretty much matched Simpson Thacher’s bonuses, it has awarded certain associates in classes of 2007 bonus amounts of $110,000 in recognition of outstanding performance. All bonuses are expected be paid out on 19 December.

Davis Polk on the other hand, has matched Simpson Thacher’s bonus range of $15,000 to $100,000, but has awarded $5,000 more for its 2008 class, and $10,000 for its 2009, 2010 and 2011 class.

The bonus scales revealed so far are understood to be: 

Simpson Thacher:

2014: $15,000

2013: $15,000

2012: $25,000

2011: $40,000

2010: $55,000

2009: $70,000

2008: $85,000

2007: $100,000

Cravath:

2014: $15,000

2013: $15,000

2012: $25,000

2011: $40,000

2010: $55,000

2009: $70,000

2008: $85,000

2007: $100,000

Skadden Arps:

2014: $15,000

2013: $15,000

2012: $25,000

2011: $40,000

2010: $55,000

2009: $70,000

2008: $85,000

2007: $100,000 – $110,000

Davis Polk:

2014: $15,000

2013: $15,000

2012: $25,000

2011: $50,000

2010: $65,000

2009: $80,000

2008: $90,000

2007: $100,000

jaishree.kalia@legalease.co.uk